Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.

Langer CJ.

J Clin Oncol. 2007 Mar 1;25(7):751-3. Epub 2007 Jan 16. No abstract available.

PMID:
17228017
[PubMed - indexed for MEDLINE]
Free Article
2.

Erlotinib in lung cancer.

Takano T, Ohe Y.

N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. No abstract available.

PMID:
16240472
[PubMed - indexed for MEDLINE]
3.

Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.

Reddy GK.

Clin Lung Cancer. 2005 Nov;7(3):163-5. Review. No abstract available.

PMID:
16354309
[PubMed - indexed for MEDLINE]
4.

The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.

Comis RL.

Oncologist. 2005 Aug;10(7):467-70. Review. No abstract available.

PMID:
16079313
[PubMed - indexed for MEDLINE]
Free Article
5.

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.

Sasaki H, Endo K, Mizuno K, Yano M, Fukai I, Yamakawa Y, Fujii Y.

Lung Cancer. 2006 Jan;51(1):135-6. Epub 2005 Nov 28. No abstract available.

PMID:
16314000
[PubMed - indexed for MEDLINE]
6.

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.

[No authors listed]

Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5. No abstract available.

PMID:
21638942
[PubMed - indexed for MEDLINE]
7.

Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?

Stinchcombe TE, Ramalingam SS.

Lancet Oncol. 2010 Jun;11(6):500-1. doi: 10.1016/S1470-2045(10)70120-0. Epub 2010 May 20. No abstract available.

PMID:
20493770
[PubMed - indexed for MEDLINE]
8.

[New era in cancer therapy. Gefitinib: small molecule--strong action].

Arnheim K.

MMW Fortschr Med. 2004 Nov 18;146(47):70-1. German. No abstract available.

PMID:
15624666
[PubMed - indexed for MEDLINE]
9.

Targeting EGFR in non-small-cell lung cancer.

Doroshow JH.

N Engl J Med. 2005 Jul 14;353(2):200-2. No abstract available.

PMID:
16014890
[PubMed - indexed for MEDLINE]
10.

[Targeted therapies. New hopes, new challenges].

Barl├ęsi F.

Rev Mal Respir. 2008 Jun;25(6):661-2. French. No abstract available.

PMID:
18772823
[PubMed - indexed for MEDLINE]
11.

Smoking history: tumor biology and clinical pharmacokinetic implications in patients with lung cancer.

Gadgeel SM.

Clin Lung Cancer. 2006 May;7(6):369-70. No abstract available.

PMID:
16800960
[PubMed - indexed for MEDLINE]
12.

Gefitinib plus docetaxel in non-small-cell lung cancer.

Costa DB, Kobayashi S.

Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60193-8. No abstract available.

PMID:
19217979
[PubMed - indexed for MEDLINE]
13.

Erlotinib in lung cancer.

Pao W, Ladanyi M, Miller VA; Lung Cancer Oncogenome Group.

N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. No abstract available.

PMID:
16240471
[PubMed - indexed for MEDLINE]
14.

Safety profile of erlotinib in patients with advanced non-small cell lung cancer with chronic renal failure.

Gridelli C, Maione P, Galetta D, Rossi A.

J Thorac Oncol. 2007 Jan;2(1):96-8. No abstract available.

PMID:
17410020
[PubMed - indexed for MEDLINE]
15.

Gefitinib plus docetaxel in non-small-cell lung cancer.

Zalcman G, Bergot E.

Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60192-6. No abstract available.

PMID:
19217981
[PubMed - indexed for MEDLINE]
16.

[Tyrosine kinase inhibitor erlotinib (Tarceva) improves survival of patients with multiple previous treatments].

[No authors listed]

Krankenpfl J. 2004;42(5-6):158. German. No abstract available.

PMID:
15527222
[PubMed - indexed for MEDLINE]
17.

Erlotinib or gefitinib for non-small-cell lung cancer.

Kaye FJ, Jantz MA, Dallas J.

N Engl J Med. 2011 Jun 16;364(24):2367; author reply 2368. doi: 10.1056/NEJMc1103918#SA2. No abstract available.

PMID:
21675909
[PubMed - indexed for MEDLINE]
18.

Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.

Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L, Shepherd FA; National Cancer Institute of Canada Clinical Trials Group.

Clin Lung Cancer. 2006 May;7(6):389-94.

PMID:
16800964
[PubMed - indexed for MEDLINE]
19.

Erlotinib in the treatment of non-small cell lung cancer.

Brown ER, Shepherd FA.

Expert Rev Anticancer Ther. 2005 Oct;5(5):767-75. Review.

PMID:
16221047
[PubMed - indexed for MEDLINE]
20.

Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.

Garfield DH.

J Clin Oncol. 2005 Oct 20;23(30):7738-40. No abstract available.

PMID:
16234533
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk